Español 
Deutsch 
Français 
MSCI World Index (MSC)
NASDAQ Composite (NASDAQ)
FTSE China A50 Index (FGI)
STOXX Europe 600 (SIX)
Nikkei 300 (OSA)
NIFTY 50 (NSE)
DAX Performance Index (XETRA)
FTSE 100 (FGI)
CAC 40 (EURONEXT)
Ascletis Pharma Inc. (1672.HK)
Hangzhou, SH, CN
Ascletis Pharma Inc., a biotechnology company, engages in the research and development, manufacture, marketing, and sale of pharmaceutical products in Mainland China. The company’s commercial products include Ritonavir tablet; and ASCLEVIR and GANOVO for use in the treatment of Hepatitis C virus. It is also developing ASC22 for treating CHB and HIV functional cure; ASC10 for treating respiratory syncytia virus; ASC10 and ASC11 to treat COVID-19; ASC40, ASC41, and ASC43F FDC for non-alcoholic steatohepatitis; and ASC42 for the treatment of primary biliary cholangitis. In addition, the company is developing ASC40 to treat recurrent glioblastoma; ASC61 for advanced solid tumors; and ASC40, an oral small molecule for the treatment of acne. Ascletis Pharma Inc. was founded in 2013 and is based in Hangzhou, the People’s Republic of China.
No mergers or acquisitions recorded for this company.
| Indicator | 1D | 1W | 2W | 3W | 1M |
|---|
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| +1.43% | -8.19% | -13.60% | -9.71% | -2.73% | +24.93% | +85.53% | +681.87% | +274.47% | +1.64% | +1.64% |
Revenue flow
Revenue by geography
Revenue by segment
Revenue composition
By product
By geography
Income Statement
Balance Sheet
Cash Flow Statement
Key Metrics
Financial Ratios
Employees
Financial Growth (CAGR)
Market Data
DCF figures are point estimates: small changes in growth or discount-rate assumptions move them materially. Read them as a reference, not a precise target.
| Rating | 2026-05 | Change |
|---|---|---|
| Strong Buy | 0 | -1 |
| Buy | 2 | 0 |
| Hold | 1 | 0 |
| Sell | 0 | 0 |
| Strong Sell | 0 | 0 |
-
Revenue growth Biotechnology: +1.6%+58.1% ★ Q4'25: -90.6% (vs Q4'23)
-
EPS growth Biotechnology: +29.7%-23.3% Q4'25: -131.8% (vs Q4'23)
-
FCF margin FCF growth · Biotechnology: +16.2%-23,271.6% Q4'25: -21,827.1% (vs Q4'23)
-
EBIT margin Biotechnology: +0.0%-23,892.1% Q4'25: -31,063.6% (vs Q4'23)
-
ROIC Biotechnology: -16.1%-1,256.5% Q4'25: -3,051.3% (vs Q4'23)
-
Share dilution Biotechnology: -3.4%-2.9% ★ Q4'25: -7.4% (vs Q4'23)
-
Debt / EBITDA Net debt/EBITDA · Biotechnology: 0.16×-0.01× Q4'25: 0.00× (vs Q4'23)
* These projections are based on analyst consensus estimates and user-defined valuation multiples. This table is for informational purposes only and does not constitute a recommendation to buy or sell any security. Past performance is not indicative of future results.
| Metric |
Dec 2018 actual |
Dec 2019 actual |
Dec 2020 actual |
Dec 2021 actual |
Dec 2022 actual |
Dec 2023 actual |
Dec 2024 actual |
Dec 2025 actual |
Dec 2026 2 Rev. Ana. 2 EPS Ana. |
Dec 2027 2 Rev. Ana. 2 EPS Ana. |
Dec 2028 2 Rev. Ana. 2 EPS Ana. |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue |
166.33M
est: 135.52M (+22.7%)
|
173.44M
est: 161.92M (+7.1%)
|
35.00M
est: 186.77M (-81.3%)
|
76.88M
est: 76.35M (+0.7%)
|
54.09M
est: 136.53M (-60.4%)
|
56.60M
est: 9.39M (+503.0%)
|
1.28M
est: 18.74M (-93.2%)
|
2.03M
est: 1.08M (+87.7%)
|
815.68M
458.92M – 1.17B
+75,387.7% YoY
|
71.01M
39.95M – 102.06M
-91.3% YoY
|
176.11M
99.08M – 253.14M
+148.0% YoY
|
| EBITDA |
-131.45M
est: -135.52M (+3.0%)
|
-73.64M
est: 7.93M (-1,028.3%)
|
-181.94M
est: -42.89M (-324.2%)
|
-169.35M
est: -64.08M (-164.3%)
|
-284.50M
est: -83.01M (-242.7%)
|
-126.09M
est: -9.39M (-1,243.4%)
|
-390.45M
est: -18.74M (-1,983.7%)
|
-471.65M
est: -1.08M (-43,548.7%)
|
-815.68M
-1.17B – -458.92M
-75,387.7% YoY
|
-71.01M
-102.06M – -39.95M
+91.3% YoY
|
-176.11M
-253.14M – -99.08M
-148.0% YoY
|
| EBIT |
-143.30M
est: -135.52M (-5.7%)
|
-95.79M
est: -34.29M (-179.3%)
|
-209.11M
est: -42.26M (-394.8%)
|
-198.89M
est: -63.13M (-215.0%)
|
-314.69M
est: -81.78M (-284.8%)
|
-144.57M
est: -9.39M (-1,440.3%)
|
-404.63M
est: -18.74M (-2,059.4%)
|
-484.53M
est: -1.08M (-44,741.2%)
|
-815.68M
-1.17B – -458.92M
-75,387.7% YoY
|
-71.01M
-102.06M – -39.95M
+91.3% YoY
|
-176.11M
-253.14M – -99.08M
-148.0% YoY
|
| Net Income |
-7.26M
est: 32.93M (-122.0%)
|
-95.97M
est: -12.53M (-666.2%)
|
-209.24M
est: -48.13M (-334.8%)
|
-199.02M
est: -71.90M (-176.8%)
|
-314.84M
est: -243.40M (-29.3%)
|
-144.72M
est: -240.43M (+39.8%)
|
-300.94M
est: -235.87M (-27.6%)
|
-359.88M
est: -323.24M (-11.3%)
|
352.79M
-360.37M – 1.22B
+209.1% YoY
|
-348.31M
-371.19M – -325.44M
-198.7% YoY
|
-350.29M
-375.14M – -325.44M
-0.6% YoY
|
| SGA |
144.42M
est: 2.25B (-93.6%)
|
125.04M
est: 2.68B (-95.3%)
|
47.79M
est: 75.00M (-36.3%)
|
37.36M
est: 1.27B (-97.0%)
|
32.41M
est: 2.26B (-98.6%)
|
62.96M
est: 222.62M (-71.7%)
|
101.74M
est: 444.45M (-77.1%)
|
75.23M
est: 25.63M (+193.5%)
|
19.35B
10.89B – 27.81B
+75,387.7% YoY
|
1.68B
947.58M – 2.42B
-91.3% YoY
|
4.18B
2.35B – 6.00B
+148.0% YoY
|
| EPS |
-0.01
est: 0.03 (-125.5%)
|
-0.15
est: -0.11 (-32.4%)
|
-0.20
est: 0.07 (-386.4%)
|
-0.18
est: -0.09 (-99.7%)
|
-0.29
est: -0.14 (-100.9%)
|
-0.13
est: -0.23 (+43.8%)
|
-0.30
est: -0.25 (-21.3%)
|
-0.37
est: -0.37 (0.0%)
|
0.44
-0.37 – 1.26
+219.9% YoY
|
-0.36
-0.38 – -0.33
-180.8% YoY
|
-0.36
-0.39 – -0.33
-0.6% YoY
|
| Date | Rating | Overall | DCF | ROE | ROA | D/E | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
| 2026-05-29 | C+ | 2/5 | 3/5 | 1/5 | 1/5 | 4/5 | 1/5 | 2/5 |
| 2026-05-28 | C+ | 2/5 | 3/5 | 1/5 | 1/5 | 4/5 | 1/5 | 2/5 |
| 2026-05-27 | C+ | 2/5 | 3/5 | 1/5 | 1/5 | 4/5 | 1/5 | 2/5 |
| 2026-05-26 | C+ | 2/5 | 3/5 | 1/5 | 1/5 | 4/5 | 1/5 | 2/5 |
| 2026-05-22 | C+ | 2/5 | 3/5 | 1/5 | 1/5 | 4/5 | 1/5 | 2/5 |
| 2026-05-21 | C+ | 2/5 | 3/5 | 1/5 | 1/5 | 4/5 | 1/5 | 2/5 |
| 2026-05-20 | C+ | 2/5 | 3/5 | 1/5 | 1/5 | 4/5 | 1/5 | 2/5 |
| 2026-05-19 | C+ | 2/5 | 3/5 | 1/5 | 1/5 | 4/5 | 1/5 | 2/5 |
| 2026-05-18 | C+ | 2/5 | 3/5 | 1/5 | 1/5 | 4/5 | 1/5 | 2/5 |
| 2026-05-15 | C+ | 2/5 | 3/5 | 1/5 | 1/5 | 4/5 | 1/5 | 2/5 |
| 2026-05-14 | C+ | 2/5 | 3/5 | 1/5 | 1/5 | 4/5 | 1/5 | 2/5 |
| 2026-05-13 | C+ | 2/5 | 3/5 | 1/5 | 1/5 | 4/5 | 1/5 | 2/5 |
| 2026-05-12 | C+ | 2/5 | 3/5 | 1/5 | 1/5 | 4/5 | 1/5 | 2/5 |
| 2026-05-11 | C+ | 2/5 | 3/5 | 1/5 | 1/5 | 4/5 | 1/5 | 2/5 |
| 2026-05-08 | C+ | 2/5 | 3/5 | 1/5 | 1/5 | 4/5 | 1/5 | 2/5 |
| 2026-05-07 | C+ | 2/5 | 3/5 | 1/5 | 1/5 | 4/5 | 1/5 | 2/5 |
| 2026-05-06 | C+ | 2/5 | 3/5 | 1/5 | 1/5 | 4/5 | 1/5 | 2/5 |
| 2026-05-05 | C | 2/5 | 2/5 | 1/5 | 1/5 | 3/5 | 1/5 | 2/5 |
| 2026-05-04 | C | 2/5 | 2/5 | 1/5 | 1/5 | 3/5 | 1/5 | 2/5 |
| 2026-04-30 | C | 2/5 | 3/5 | 1/5 | 1/5 | 3/5 | 1/5 | 2/5 |
| 2026-04-29 | C | 2/5 | 3/5 | 1/5 | 1/5 | 3/5 | 1/5 | 2/5 |
| 2026-04-28 | C | 2/5 | 3/5 | 1/5 | 1/5 | 3/5 | 1/5 | 2/5 |
| 2026-04-27 | C | 2/5 | 3/5 | 1/5 | 1/5 | 3/5 | 1/5 | 2/5 |
| 2026-04-24 | C | 2/5 | 3/5 | 1/5 | 1/5 | 3/5 | 1/5 | 2/5 |
| 2026-04-23 | C | 2/5 | 3/5 | 1/5 | 1/5 | 2/5 | 1/5 | 2/5 |
| 2026-04-22 | C | 2/5 | 3/5 | 1/5 | 1/5 | 2/5 | 1/5 | 2/5 |
| 2026-04-21 | C | 2/5 | 3/5 | 1/5 | 1/5 | 2/5 | 1/5 | 2/5 |
| 2026-04-20 | C | 2/5 | 3/5 | 1/5 | 1/5 | 2/5 | 1/5 | 2/5 |
| 2026-04-17 | C | 2/5 | 3/5 | 1/5 | 1/5 | 2/5 | 1/5 | 2/5 |
| 2026-04-16 | C | 2/5 | 3/5 | 1/5 | 1/5 | 2/5 | 1/5 | 2/5 |
| 2026-04-15 | C | 2/5 | 3/5 | 1/5 | 1/5 | 2/5 | 1/5 | 2/5 |
| 2026-04-14 | C | 2/5 | 3/5 | 1/5 | 1/5 | 2/5 | 1/5 | 2/5 |
Owner Earnings
Ownership Overview
Ownership breakdown not available.
No beneficial ownership filings recorded.
Institutional Activity (13F)
Institutional history not available.
Top holders not available.
Insider Activity
No insider activity available.
Insider history not available.
No recent insider transactions.
Executive team
Executive compensation
Executive compensation not available.
No CEO compensation history available.
Proxy statements
No proxy statements available for this company yet.
Recent SEC filings
No SEC filings available for this company yet.
Executive team
| Name | Title | Compensation | Gender |
|---|---|---|---|
| Jinzi Wu | Founder, Chairman & Chief Executive Officer | 118M | — |
| Hejingdao Wu | Senior Vice President of Operations & Executive Director | 7M | female |
| George Zhengzhi Hill | Senior Consultant & Chief Medical Advisor | — | — |
| John Gargiulo | Chief Business Officer | — | male |
| Kristjan Sigurdur Gudmundsson | Senior Consultant & Head of Discovery | — | — |
| Ming Fai Chung | Company Secretary | — | male |
No data available for this company.
No Senate trading activity found for this company.
No House trading activity found for this company.
Share your view on this stock and instantly see how the community has voted over the last 6 months.
Community Opinion for 1672.HK
Short-term intention
Target Price Distribution
These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.
